Pembrolizumab

Pembrolizumab Reactions 1704, p300 - 2 Jun 2018 Focal immune-related pancreatitis: case report A 76-year-old woman developed focal immune-related pancreatitis following treatment with pembrolizumab. The woman, who had urothelial carcinoma and local nodal recurrence, started receiving treatment with IV pembrolizumab 200 mg/3 weeks. Her concurrent treatment included R0 nephroureterectomy, methotrexate, vinblastine, adriamycin and cisplatin. Subsequently, she developed grade 2 diarrhoea and weight loss. Further CT examination revealed mild dilation of the main pancreatic duct (MPD). Subsequent MRI and cholangiopancreatography confirmed MPD dilation secondary to a tapered stricture in the pancreatic head. On diffusion-weighted image, a marked increase in signal intensity of a region of the pancreatic head was observed, indicating restricted diffusion. A subsequent endoscopic ultrasound (EUS) revealed a 2cm hypoechoic solid lesion of the pancreatic neck, stiff at elastography, with low vascularity after the administration of contrast agent, causing stenosis of the MPD with upstream dilation. Therefore, pancreatic adenocarcinoma was suspected. However, fine-needle aspiration was found to be negative for neoplasia, but revealed a dense granulocytic inflammation. Subsequent laboratory investigation revealed decreased level of faecal elastase 41 mcg/g (normal>200) suggestive of exocrine pancreatic insufficiency. Therefore, the woman was treated with pancreatic enzyme replacement therapy. Subsequently, prompt diarrhoea resolution and weight gain was observed. Two months later, a follow-up EUS revealed disappearance of the lesions and only finding of hypoechoic and inhomogeneous parenchyma, diffuse hyperechoic foci and strands, with pancreatic head atrophy. The MPD was found to be thin and irregular. According to the Rosemont classification, these findings were consistent with chronic pancreatitis. Additionally, distal common bile duct and superior mesenteric artery demonstrated thickening of walls (1 and 1.6mm, respectively), as in cases of cholangitis and vasculitis. Two months later, an MRI scan using diffusion-weighted imaging revealed absence of any solid pancreatic lesion. She remained asymptomatic, although faecal elastase levels remained low. Her final diagnosis was focal immune-related pancreatitis considered to be secondary to pembrolizumab treatment [duration of treatment to reaction onset not stated]. Author comment: "We believe that clinicians using these drugs [pembrolizumab] should be aware that immune-related pancreatitis might present without amylase or lipase increase or overt symptoms of acute pancreatitis but possibly as a focal pancreatic lesion, and with diarrhoea and weight loss due to [exocrine pancreatic insufficiency], which might be appreciated by careful imaging procedures and measure of faecal elastase levels." Capurso G, et al. Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis? European Journal of Cancer 95: 123-126, May 2018. Available from: URL: http:// doi.org/10.1016/j.ejca.2018.02.006 - Italy 803323324 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Pembrolizumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/pembrolizumab-3Mud2xZTeL
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46943-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p300 - 2 Jun 2018 Focal immune-related pancreatitis: case report A 76-year-old woman developed focal immune-related pancreatitis following treatment with pembrolizumab. The woman, who had urothelial carcinoma and local nodal recurrence, started receiving treatment with IV pembrolizumab 200 mg/3 weeks. Her concurrent treatment included R0 nephroureterectomy, methotrexate, vinblastine, adriamycin and cisplatin. Subsequently, she developed grade 2 diarrhoea and weight loss. Further CT examination revealed mild dilation of the main pancreatic duct (MPD). Subsequent MRI and cholangiopancreatography confirmed MPD dilation secondary to a tapered stricture in the pancreatic head. On diffusion-weighted image, a marked increase in signal intensity of a region of the pancreatic head was observed, indicating restricted diffusion. A subsequent endoscopic ultrasound (EUS) revealed a 2cm hypoechoic solid lesion of the pancreatic neck, stiff at elastography, with low vascularity after the administration of contrast agent, causing stenosis of the MPD with upstream dilation. Therefore, pancreatic adenocarcinoma was suspected. However, fine-needle aspiration was found to be negative for neoplasia, but revealed a dense granulocytic inflammation. Subsequent laboratory investigation revealed decreased level of faecal elastase 41 mcg/g (normal>200) suggestive of exocrine pancreatic insufficiency. Therefore, the woman was treated with pancreatic enzyme replacement therapy. Subsequently, prompt diarrhoea resolution and weight gain was observed. Two months later, a follow-up EUS revealed disappearance of the lesions and only finding of hypoechoic and inhomogeneous parenchyma, diffuse hyperechoic foci and strands, with pancreatic head atrophy. The MPD was found to be thin and irregular. According to the Rosemont classification, these findings were consistent with chronic pancreatitis. Additionally, distal common bile duct and superior mesenteric artery demonstrated thickening of walls (1 and 1.6mm, respectively), as in cases of cholangitis and vasculitis. Two months later, an MRI scan using diffusion-weighted imaging revealed absence of any solid pancreatic lesion. She remained asymptomatic, although faecal elastase levels remained low. Her final diagnosis was focal immune-related pancreatitis considered to be secondary to pembrolizumab treatment [duration of treatment to reaction onset not stated]. Author comment: "We believe that clinicians using these drugs [pembrolizumab] should be aware that immune-related pancreatitis might present without amylase or lipase increase or overt symptoms of acute pancreatitis but possibly as a focal pancreatic lesion, and with diarrhoea and weight loss due to [exocrine pancreatic insufficiency], which might be appreciated by careful imaging procedures and measure of faecal elastase levels." Capurso G, et al. Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis? European Journal of Cancer 95: 123-126, May 2018. Available from: URL: http:// doi.org/10.1016/j.ejca.2018.02.006 - Italy 803323324 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off